Search Within

Kenneth K Ng

  1. "Matthew Fury"
Formats
  1. Journal Article (2)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (4)
  2. Head and Neck Service (4)
  3. Neuroradiology Service (4)
  4. Radiology, Department of (4)
  5. Solid Tumor Oncology Division (4)
  6. Thoracic Oncology (4)

More Groups

People
  1. David Pfister (4)
  2. Eric Sherman (4)
  3. Matthew Fury (4)
  4. Sofia Haque (4)
  5. Stephanie Smith-Marrone (4)
  6. Boris Mueller (2)

More People

Years
  1. 2014 (1)
  2. 2013 (1)
  3. 2012 (1)
  4. 2011 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. Journal of the National Comprehensive Cancer Network (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Harborside Press (1)
  3. Oxford University Press (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S.; Smith-Marrone, S.; Mueller, B.; Ng, K. K.; Dutta, P. R.; Gelblum, D. Y.; Lee, J. L.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S. L.; Smith-Marrone, S.; Ng, K. K.; Mueller, B.; Gelblum, D. Y.; Dutta, P. R.; Lee, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save